RUA vs. POLX, MHC, SUN, DEMG, BELL, IHC, GENF, GDR, ROQ, and LLAI
Should you be buying RUA Life Sciences stock or one of its competitors? The main competitors of RUA Life Sciences include Polarean Imaging (POLX), MyHealthChecked (MHC), Surgical Innovations Group (SUN), Deltex Medical Group (DEMG), Belluscura (BELL), Inspiration Healthcare Group (IHC), Genflow Biosciences (GENF), genedrive (GDR), Roquefort Therapeutics (ROQ), and LungLife AI (LLAI). These companies are all part of the "medical" sector.
Polarean Imaging (LON:POLX) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
Polarean Imaging has a net margin of 0.00% compared to Polarean Imaging's net margin of -100.05%. Polarean Imaging's return on equity of -40.56% beat RUA Life Sciences' return on equity.
Polarean Imaging received 23 more outperform votes than RUA Life Sciences when rated by MarketBeat users. Likewise, 67.65% of users gave Polarean Imaging an outperform vote while only 0.00% of users gave RUA Life Sciences an outperform vote.
RUA Life Sciences has higher revenue and earnings than Polarean Imaging. RUA Life Sciences is trading at a lower price-to-earnings ratio than Polarean Imaging, indicating that it is currently the more affordable of the two stocks.
23.4% of Polarean Imaging shares are held by institutional investors. Comparatively, 20.7% of RUA Life Sciences shares are held by institutional investors. 28.0% of Polarean Imaging shares are held by insiders. Comparatively, 18.8% of RUA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Polarean Imaging has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, RUA Life Sciences has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.
In the previous week, Polarean Imaging had 1 more articles in the media than RUA Life Sciences. MarketBeat recorded 1 mentions for Polarean Imaging and 0 mentions for RUA Life Sciences. RUA Life Sciences' average media sentiment score of 0.00 equaled Polarean Imaging'saverage media sentiment score.
Summary
Polarean Imaging beats RUA Life Sciences on 9 of the 14 factors compared between the two stocks.
Get RUA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RUA Life Sciences Competitors List
Related Companies and Tools
